Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Regenerative Medical Technology (RMTG) over the last 6 years, with Q3 2025 value amounting to -$224829.0.

  • Regenerative Medical Technology's Cash from Investing Activities fell 31939.45% to -$224829.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$381094.0, marking a year-over-year increase of 1520.33%. This contributed to the annual value of -$215419.0 for FY2024, which is 4413.35% up from last year.
  • According to the latest figures from Q3 2025, Regenerative Medical Technology's Cash from Investing Activities is -$224829.0, which was down 31939.45% from -$50000.0 recorded in Q4 2024.
  • In the past 5 years, Regenerative Medical Technology's Cash from Investing Activities ranged from a high of $916647.0 in Q3 2021 and a low of -$284002.0 during Q4 2023
  • For the 5-year period, Regenerative Medical Technology's Cash from Investing Activities averaged around $1602.6, with its median value being -$52657.0 (2024).
  • In the last 5 years, Regenerative Medical Technology's Cash from Investing Activities skyrocketed by 83331.76% in 2021 and then tumbled by 3797055.56% in 2022.
  • Over the past 5 years, Regenerative Medical Technology's Cash from Investing Activities (Quarter) stood at -$180.0 in 2021, then tumbled by 37970.56% to -$68527.0 in 2022, then plummeted by 314.44% to -$284002.0 in 2023, then surged by 82.39% to -$50000.0 in 2024, then plummeted by 349.66% to -$224829.0 in 2025.
  • Its Cash from Investing Activities stands at -$224829.0 for Q3 2025, versus -$50000.0 for Q4 2024 and -$53608.0 for Q3 2024.